omniture
logo
Search
上海璎黎药业有限公司 Shanghai Maya Li Pharmaceutical Co. Ltd
Media Room

Latest News

rss

Yingli Pharma Announces Successful End-of-Phase 2 Meeting with FDA and Clearance of Global Multi-center Phase 3 Registration Study Design of Linperlisib for the Treatment of Relapsed and/or Refractory Peripheral T-cell Lymphoma

SAN FRANCISCO, April 1, 2025 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharm...

2025-04-01 22:00 3125

Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Meeting

Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable s...

2023-12-11 21:00 2084

280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in patients with advanced cancers harboring mutations in KRAS, HRAS, or NRAS

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2023 /PRNewswire/ -- 280Bio, Inc., a clinical stage biotechnol...

2023-12-01 21:00 1919

280 Bio receives IND approval from the FDA for YL-17231

---The Company announces to initiate Phase 1 Clinical Trial with the KRAS inhibitor YL-17231 in US-...

2023-07-07 20:00 3423

280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting

A broadly acting KRAS Inhibitor, TEB-17231, robustly blocks tumor growth and overcomes KRASG12C inh...

2023-03-21 20:00 2210

Yingli Pharma Announces a presentation on the Phase 2 clinical trial of linperlisib, a PI3Kδ selective inhibitor, in relapsed or refractory follicular lymphoma at the European Hematology Association 2021 Congress

SHANGHAI, June 11, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clin...

2021-06-11 13:05 2919

Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annual Meeting

Clinical trial data will be updated in three presentations on lead drug candidates * Linperlisib...

2021-06-04 14:29 2697